Abstract:Abstract Background The new European Medicines Agency (EMA) Clinical Trials Information System (CTIS), based on the Clinical Trials Regulation (CTR EU 536/2014), came into full effect on 31 January 2022 and was intended to provide an easier, more streamlined approach to the registration of clinical trials taking place in Europe. Using the experience gained on the new regulatory framework from three multi-national European clinical research studies of outbreak-prone infectious diseases, this article describes the advantages and shortcomings of the new clinical trial submission procedure. Methods We report the time to approval, size of the application dossier, and number of requests for information (RFIs) for each study. We also explore the experience of each study within the regulatory framework and its use of CTIS to document the real-world, practical consequences of the system on individual studies. The study assesses the experience of three multi-country studies conducted in Europe working within the EU and non-EU regulatory environments. Results While the time to regulatory and ethical approval has improved since the implementation of the new regulation, the timelines for approvals are still unacceptably slow, particularly for studies being conducted in the context of an evolving outbreak. Within the new regulatory approval procedure, there is evidence of conflicting application requirements, increased document burden, barriers to submitting important modifications, and debilitating technical hurdles. Conclusions CTIS promised to lower the administrative bar, but unfortunately this has not been achieved. There are challenges that need to be urgently confronted and addressed for international research collaborators to effectively manage health crises in the future. While the value of multi-national outbreak research is clear, the limitations and delays imposed by the system, which raise challenging ethical questions about the regulation, are prejudicial to all clinical research, especially publicly funded academic studies. This report is relevant to both regulators and clinical researchers. It is hoped that these findings can help improve pan-European clinical trials, especially for the purpose of epidemic preparedness and response. Trial registration This paper references experiences gained during management of three pan-European trials: EU-SolidAct’s Bari-SolidAct (CT No. 2022-500385-99-00 - 15 March 2022) and AXL-SolidAct (CT No. 2022-500363-12-00 - 19 April 2022), and MOSAIC (CT No. 2022-501132-42-00 - 22 June 2022).

Regulatory challenges associated with conducting multicountry clinical trials in resource-limited settings

Multi-regional clinical trials and global drug development

Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions

Regulatory approval of clinical trials: is it time to reinvent the wheel?

Performing clinical drug trials in children with a rare disease

Global Randomized Trials: the Promise of India and China.

Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges

Experiences and challenges with the new European Clinical Trials Regulation

Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches

A landscape analysis of clinical trials and infant clinical trials in Kenya, Ethiopia, and Nigeria

Clinical trials in "emerging markets": regulatory considerations and other factors

Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials

The necessary conduct: Exploratory multiregional clinical trials in East Asia

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Challenges of developing and conducting clinical trials in rare disorders

Global Disparities in Access to Vaccine Clinical Trials: A Review of the Literature

Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective

The challenges of regulatory pluralism

Research report on guidance for the multi-regional clinical trials

Linguistic and Cultural Challenges in Communication and Translation in US-Sponsored HIV Prevention Research in Emerging Economies

Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems